Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $55 | $61 | $107 | $150 |
| - Cash | $35 | $40 | $48 | $38 |
| + Debt | $17 | $14 | $15 | $17 |
| Enterprise Value | $36 | $35 | $74 | $129 |
| Revenue | $174 | $2 | $2 | $13 |
| % Growth | 7,375.2% | 6.1% | -83.2% | – |
| Gross Profit | $174 | $2 | $2 | $10 |
| % Margin | 100% | 77.8% | 80.6% | 77.6% |
| EBITDA | -$9 | -$11 | -$12 | $2 |
| % Margin | -5.4% | -485.6% | -536.9% | 14.3% |
| Net Income | -$10 | -$12 | -$13 | $1 |
| % Margin | -5.7% | -504.6% | -574% | 5.8% |
| EPS Diluted | -1.93 | -2.31 | -2.51 | 0.13 |
| % Growth | 16.5% | 8% | -2,030.8% | – |
| Operating Cash Flow | -$5 | -$11 | -$2 | $2 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$5 | -$11 | -$2 | $2 |